· ST-SPC-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
The question is whether the heart-protective effect of statins holds in people with diabetes. In this set of papers, diabetics who took statins, took stronger doses, or took them longer had fewer heart attacks, strokes and cardiac deaths [13][14], and a related trial showed that lowering cholesterol further still helped diabetics already on a statin [17]. However, the only study here that tested a statin directly against a dummy pill did so in diabetics on dialysis and did not show a benefit on its main measure [3]. The cohort studies that most directly support the broad claim are observational, so they can show an association but cannot prove the statin caused the difference. The landmark statin-versus-placebo trials in ordinary diabetics are not in this collection; they appear only inside review articles that were set aside. The panel therefore treated the direction of benefit as consistent but the hard proof as incomplete.
A Korean cohort of diabetics found lower cardiovascular risk with moderate- or high-intensity versus low-intensity statins (HR 0.72; p=0.027) and with longer duration of therapy (adjusted HR 0.70; p=0.009) [13]. In an acute-myocardial-infarction registry of 11,962 patients, cardiac events were significantly more frequent in statin nonusers than users across normoglycaemic, prediabetic and diabetic groups [14]. In a prespecified diabetic subgroup, adding ezetimibe to simvastatin lowered the 7-year event rate by 5.5% absolute (HR 0.85; 95% CI 0.78-0.94) [17]. The single statin-versus-placebo RCT present, in 1255 diabetics on hemodialysis, was null on its composite primary endpoint (RR 0.92; 95% CI 0.77-1.10; P=0.37) though it reduced all cardiac events combined (RR 0.82; 95% CI 0.68-0.99; P=0.03) [3]. The contested point: The evidence divides on design: the only direct statin-versus-placebo trial [3] is null on its primary endpoint, while the sources that support the broad claim are either observational [13][14] or test cholesterol lowering by a non-statin agent on a statin background [17]. The split is whether an internally consistent but indirect signal should count as demonstrating statin-specific causal benefit in general diabetics.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only statin-vs-placebo RCT in the usable corpus [3] is null on its primary composite endpoint (RR 0.92, 95% CI 0.77-1.10, P=0.37) — the strongest design present does not demonstrate benefit.
Direct support for the general claim rests on observational cohorts [13] and [14], which are open to healthy-adherer bias and confounding-by-indication and cannot establish causation.
Where it remains uncertain. The strongest design in the corpus, a statin-versus-placebo RCT in hemodialysis diabetics [3], missed its primary endpoint (RR 0.92; 95% CI 0.77-1.10; P=0.37), and no clean confirmatory RCT in general diabetics is present.
Aleatory
The only statin-versus-placebo RCT [3] has a primary-endpoint interval spanning 0.77 to 1.10, so chance variation around a null point estimate is consistent with the data.
Epistemic
The corpus contains no statin-versus-placebo trial in general (non-dialysis) diabetics; such evidence appears only inside the study-type-excluded reviews [8][19].
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Countervailing direct RCT: null primary result in a diabetic hemodialysis subpopulation
“Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.”
Panel auditInternal validity: high · scope of inference: Statin cardiovascular benefit in type 2 diabetics receiving maintenance hemodialysis specifically.Key limitations: hemodialysis population only · null primary endpoint · signal of increased fatal stroke
Dose-response signal for statin benefit within a T2DM cohort
“The hazard ratio (HR) of MACE was lower in patients receiving moderate- or high-intensity statins than in those receiving low-intensity statins (HR, 0.72; p = 0.027)”
Panel auditInternal validity: medium · scope of inference: Effect of statin intensity, achieved LDL and duration on MACE in type 2 diabetes.Key limitations: no statin-free comparator · observational confounding · intensity not statin-versus-none contrast
Observational support: statin use associated with lower CV events in T2DM and prediabetes AMI patients
“in all the 3 glycemic groups, the cumulative incidences of MACE, all-cause death, and CD were significantly higher among statin nonusers than among statin users”
Panel auditInternal validity: low · scope of inference: Statin treatment and 2-year outcomes in post-PCI AMI patients with prediabetes or type 2 diabetes.Key limitations: observational registry · confounding by indication · AMI secondary-prevention population
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direction of effect is consistent across included sources but the direct evidence is observational and the one RCT present is null, placing confidence at the lower edge of Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No clean statin-versus-placebo RCT in general diabetics. The claim's strongest possible support, a direct randomised comparison in ordinary diabetics, is absent from the retained corpus; the only present RCT is in a dialysis subpopulation [3]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A statin-versus-placebo randomised trial, or individual-patient meta-analysis of such trials, in general (non-dialysis) diabetic populations with MACE as the primary endpoint.
Open question: Does a statin versus placebo reduce MACE in general diabetic populations without prior cardiovascular disease? Why it is still open: The only retained statin-versus-placebo RCT [3] is in hemodialysis diabetics and null on its primary endpoint; no primary-prevention diabetic RCT is present.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19